Taiwan import license bolsters George Clinical's abilities in Asia-Pacific

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/bedo)
(Image: Getty/bedo)

Related tags: George Clinical, Asia-pacific, Clinical trial, Clinical data, Taiwan, Clinical trial site

George Clinical receives license to import clinical trial supply into Taiwan as the Asia-Pacific region continues to develop as a clinical trial site.

The global contract research organization (CRO), which is based in Sydney with offices in Hong Kong, Beijing, Shanghai and Bengaluru, was granted a license to import drugs into Taiwan on behalf of sponsors for clinical trials.

This license will enable George Clinical to provide import services to small and mid-sized clinical trial clients who do not have an entity in Taiwan, as it would otherwise and previously rely on large individual pharmaceutical companies to import on its behalf.

George Clinical stated that with this license in Taiwan it can now serve as a one-stop-shop provider for sponsors looking to expand into Taiwan for trials. Before this license, George Clinical was only able to provide project and site management to its clients instead of drug management.

Additionally, George Clinical now offers drug importation for renewals and amendments, investigational medicinal product (IMP) stock management, closure and inspection after clinical study report submission, re-labeling, return and destruction.

Taiwan, and the Asia-Pacific region are growing as clinical trial locations. The region has a large and diverse patient population​, CROs like Premier Research and PSI CRO​ have both expanded into Taiwan within the last two years.

Premier Research’s VP and head of Asia Pacific, Ashish Jain, previously told us that economic growth​ in the region and greater patient access to new drugs has led to an amplified demand for clinical trials. PSI CRO’s head of corporate development also told us that the country has become an important contributor to global clinical trials after it opened an office in Taipei in 2017. 

Related news

Show more

Related products

show more

Local Lab Data Management

Local Lab Data Management

Q2 Solutions | 01-Jul-2020 | Technical / White Paper

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Related suppliers

Follow us

Products

View more

Webinars